Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06244433

Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome

This is a multicenter genetic study aimed at identifying new genes/variants associated with sudden infant death syndrome (SIDS) based on whole-genome sequencing of family trios

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Nantes University Hospital, Nantes, Loire-Atlantique, France

Loading trial locations.

About this study

The present project is part of a more global project called BIOMINRISK for which 3 axes will be explored: Genetics (a project which will be detailed here), Neurobiology and Radio-anatomical.

This is a multicenter (15 centers), national, non-randomized, open-label, genetic study. Sudden unexpected death in infant (SUDI) cases will be included (i) partly retrospectively (infants already included in the national French SUDI registry) and (ii) for the other cases, prospectively at the time of care of the deceased infant by the referral center of SUDI participating in the project. The parents making up the trios will be included prospectively.

Once the Sudden infant death syndrome (SIDS) cases have been identified among all the included SUDI cases (following the results of post-mortem examinations), Whole Genome Sequencing (WGS) will be carried out on these SIDS cases and their two parents, in order to identify pathogenic allelic variants. The data generated by this sequencing will then be analyzed using a trio approach to search for de novo variants, i.e. variants present in the infant who died of SIDS and absent from the genome of both parents.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Child Inclusion Criteria

  • Death of a child between 0 and 2 years of age due to sudden unexpected death in infant
  • Child included in the French SUDI registry with effective participation in the biocollection
  • Children who also meet the inclusion criteria for the BIOMINRISK-NEUROBIO (axis 2) and BIOMINRISK-RADIO-ANAT (axis 3) studies in the overall BIOMINRISK project.

Parents Inclusion Criteria

  • Biological parents of the child included in the BIOMINRISK study
  • Parents who have both signed the consent form for blood collection and inclusion of their samples in the biocollection
  • parents beneficiaries of a social security or similar scheme

Child Exclusion Criteria:

  • Presence of a known metabolic, genetic or syndromic pathology at the time of death

Parents Exclusion Crtiteria:

  • Parent under guardianship
  • Presence of a known metabolic, genetic or syndromic pathology

Treatment and study plan

Whole Genome Sequencing

Genetic

Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants

Primary outcomes

  1. Identification of genetic variants

    Time frame: up to 38 months

    Presence of de novo genetic point mutations in coding and non-coding sequences, based on analysis of family trios using a whole-genome sequencing approach

Secondary outcomes

  1. Identification of heterozygous variants or CNVs (copy number variants)

    Time frame: up to 38 months

    Presence of composite heterozygous variants or CNVs (copy number variants) in the coding and non-coding sequences of the MSN propositus genome

  2. Identification of new genotype - phenotype correlations

    Time frame: up to 38 months

    Presence of new correlations between identified genetic variants and clinical and biological characteristics identified

Study contacts

Contact information is provided by the study sponsor or research team.

Alban-Elouen BARUTEAU

CONTACT

[email protected]

Fleur Lorton

CONTACT

[email protected]

33 2 40 08 38 06

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • AXA Assurances VIE Mutuelle
  • Institut du Thorax

Registry information

Official study title

Risk Stratification of Sudden Unexpected Death in Infant Based on Biomarkers - Identification of Genetic Variants Associated With Unexpected Infant Death Syndrome

Acronym: BIOMINRISK

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Feb 6, 2024
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.